MorphImmune Inc.

Overview

• HeadquartersDE¹
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

MorphImmune Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorClay B. Siegall, Ph.D. named May 17, 2023²
• DirectorFranklyn Prendergast, M.D., Ph.D. named May 17, 2023²
• DirectorIsaac Barchas named Feb 17, 2022 to May 17, 2023²
• DirectorPhilip Low, Ph.D. named Feb 17, 2022 to May 17, 2023²
• DirectorRonald Martell named Feb 17, 2022 to May 17, 2023²
• DirectorSunil Singhal, M.D. named Feb 17, 2022 to May 17, 2023²

Filings

2 filings to the SEC since October 2021: 2 private raises. The latest 2:

1. May 17, 2023D EDGAR
2. Feb 17, 2022D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

MorphImmune Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• Immunome Inc.SC 13D Jul 7, 2023³

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. May 5, 2023Raised $15 million in a private offering of equity² Form D: 11 investors so far Form D
2. Feb 4, 2022Raised $17.1 million in a private offering of equity⁴ Form D: $19 million offered in all Form D